Market Research Report - 252846
Global Markets for Treatments for Syndromes of Progressive Ataxia and Weakness Disorders -- Focus on Weakness Disorders
|Published by||BCC Research|
|Published||Content info||144 Pages|
|Global Markets for Treatments for Syndromes of Progressive Ataxia and Weakness Disorders -- Focus on Weakness Disorders|
|Published: October 18, 2012||Content info: 144 Pages||
The global market for treatments for syndromes of progressive ataxia and weakness disorders was valued at nearly $14 billion in 2011 and should reach nearly $15 billion in 2012. Total market value is expected to reach nearly $23.5 billion in 2017 after increasing at a five-year compound annual growth rate (CAGR) of 9.4%.
Treatments for progressive weakness syndromes should total nearly $14.6 billion in 2012 and $22.8 billion in 2017, a CAGR of 9.4%.
Treatments for multiple sclerosis should total nearly $12.6 billion in 2012 and $19.5 billion in 2017, a CAGR of 9.2%.
GLOBAL MARKET FOR PROGRESSIVE ATAXIA AND WEAKNESS DISORDERS,
2010-2017 ($ MILLIONS)
Source: BCC Research
BCC's goal in conducting this study is to provide an overview of the current and future characteristics of the global market for treatments of neurodegenerative (i.e., progressive ataxia and weakness) disorders. The key objective is to present a comprehensive analysis and the future direction of treatments for these disorders as the market efforts toward drug and therapy development evolve.
This report explores present and future strategies within the progressive ataxia and weakness disorders market, which includes treatments and therapies for dysfunctions, including progressive ataxia and progressive weakness disorder syndromes. The market's improvisation, setbacks and needs are also discussed. The comparisons, usage, advantages and disadvantages of different types of technologies, including small-molecule and monoclonal antibodies, are also presented.
A detailed analysis of the industry structure has been conducted. Revenues are broken down by the neurodegenerative dysfunction. Sales figures are estimated for the five-year period from 2012 through 2017.
The report discusses applications for neurodegenerative disorder treatment and therapy technologies, with emphasis on small-molecule and monoclonal antibodies technology. The report also covers significant patents and their allotments in each category.
Extensive research in the field of progressive ataxia and weakness disorders as well as collaborations with research institutes have highlighted the importance of understanding the nature of these disorders. New technology development is providing modifying therapies for the late stages of these disorders. Collaborations among research institutes and pharmaceutical companies are becoming more common, as state-of-the-art technology is being explored to develop more-efficient products and therapies.
R&D spending, increasing competition, patent expiries and new technologies are shifting the market in a new direction. The market's overall revenue has increased from 2009 to 2011, and it continues to show growth, as new advancements, product launches and collaborations will have positive influences for the foreseeable future. This study looks at most of the systems affected by these factors.
Acquisition strategies and company collaborations are also covered in this report. This study discusses the strength and weaknesses of each technology in light of the new developments, growing competition and changing customer needs.
The scope of this study encompasses the neurodegenerative (i.e., progressive ataxia and weakness) disorders in the pharmaceutical and biotechnology markets. BCC analyzes each market and its applications, the regulatory environments, and the technologies involved, as well as market projections and market shares. Technological issues include the latest trends and developments. The emerging market for enzyme inhibitors includes such countries as India, China, Japan, South Korea, Taiwan, Canada, Africa, Australia and New Zealand.
Many companies within the industry were surveyed to obtain data for this study. These included manufacturers and end users of enzyme inhibitors in therapeutic categories and various disease-sector industries. Data were gathered from various industry sources. BCC spoke with officials within the industry and also reviewed newsletters, company literature and product literature, as well as a host of technical articles, journals, indices and abstracts. Exhaustive investigations of databases by key terminology were completed. In addition, data were compiled from current financial, trade and government sources.
A team of professionals in the biotechnology industry has carried out this study. Its project manager is Shalini S. Dewan, who holds a Master's degree in pharmaceutical chemistry and has more than 14 years of industry experience. She has covered such research topics as compounds of potential pharmaceutical interest from ibuprofen and 2-naphthyl acetic acid. Shalini was awarded a Gold Medal by the Prime Minister of India for her work, and she has collaborated with top companies in India and in the U.S.